This page shows that usual window by date for your own course. Then it goes through how common hair loss is on Zepbound and on Wegovy, whether the drug or the weight loss is responsible, which types of hair loss have been linked to these drugs, whether it grows back, what the dermatology reviews recommend, and when to see a specialist.
When would shedding start and stop for me?
Enter the date of your first dose and the week your weight levelled off, or the week you expect it to. The calendar applies the usual timing of weight-loss shedding from the dermatology literature.
Log your weight each week in the app and it shows when the fast phase ends.
Open the appThe numbers along the bottom are weeks of treatment, and the white line is today. Shedding is placed 2 to 3 months after the weight loss that sets it off, and regrowth 3 to 6 months after the weight levels off. These are the usual timings from reviews of weight-loss shedding. Most people on Zepbound have no noticeable hair loss at all.
The calendar rests on one idea. The usual form of hair loss after weight loss is called telogen effluvium. A stress on the body pushes a share of the hair follicles into their resting phase early, and the hairs fall out when that phase ends. A 2026 review in a dermatology journal describes the result as "diffuse hair shedding after 2–3 months of a triggering event".3 The delay is the important part: the hair that falls today was set off by something that happened two or three months ago.
On Zepbound the trigger is not a single day. Weight falls fastest in the first 24 weeks and keeps falling, more slowly, until it levels off.7 So the window in which shedding can begin is long. It opens about two months after the first dose and stays open until about three months after the fast phase of weight loss has ended.
| Timing | Figure | Source |
|---|---|---|
| Shedding appears after the trigger | 2 to 3 months | 2026 dermatology review |
| Regrowth after the weight is stable | within 3 to 6 months | 2026 dermatology review |
| Recovery period in 140 patients with weight-loss shedding | 4.8 months on average, range 0.5 to 16 | hospital study, 2024 |
| Weight lost by those 140 patients | 15.2% on average, at 3.5 kg a month | hospital study, 2024 |
Seyed Jafari and colleagues, American Journal of Clinical Dermatology 2026. Kang and colleagues, Annals of Dermatology 2024.
The hospital study is worth a closer look, because its patients were not on any weight-loss drug. They had lost weight by dieting, through illness or after surgery, and came to a dermatology clinic with diffuse shedding. On average they had lost 15.2% of their weight at a rate of 3.5 kg a month.4 That is close to what Zepbound produces in its first months: in the main trial the average loss was about 8% in 12 weeks, around 3 kg a month for a 105 kg person. The trigger on Zepbound is the same trigger as in that clinic.
How common is hair loss on Zepbound?
Uncommon overall, and much more common in women than in men. The label gives the figures from its two main trials.1
Each dot is one person in a hundred. Figures from the labels' side effect sections. Zepbound: all doses pooled. The dots are rounded to whole people.
| Reported hair loss | Women on the drug | Women on placebo | Men on the drug | Men on placebo |
|---|---|---|---|---|
| Zepbound, all doses | 7.1% | 1.3% | 0.5% | 0% |
| Wegovy 2.4 mg | 4% | 2% | 0.9% | 0% |
| Wegovy 2.4 mg, in the high-dose trials | 5.4% | 1.5% | 0% | 0% |
| Wegovy 7.2 mg | 8.4% | 1.5% | 0.2% | 0% |
Zepbound label and Wegovy label, section 6.1 of each.
About seven women in a hundred on Zepbound reported hair loss, where about one in a hundred did on placebo. So six of those seven are the drug's share, or the share of the weight loss it caused. Among men the figure was one in two hundred.
By dose, the Zepbound label's main table shows no trend: hair loss was reported by 5, 4 and 5 in 100 people on 5, 10 and 15 mg, against 1 in 100 on placebo. Nobody taking Zepbound left the trials because of it. One person on placebo did.1
These are counts of people who mentioned hair loss to the trial staff. Nobody counted hairs or examined scalps, so mild shedding that a participant did not report is not in the figures, and neither is the severity of what was reported.
Is it the drug or the weight loss?
The weight loss, on the evidence available. Both labels use the same sentence: hair loss adverse reactions "were associated with weight reduction".12
Three observations fit that reading. The first is the Wegovy dose comparison. In the trials of the 7.2 mg dose, people on 7.2 mg lost more weight than people on 2.4 mg, 18.8% against 15.5%, and they reported more hair loss, 5.8% against 3.3%. More weight off went with more hair lost.
The second is the clinic study above. People who had never taken these drugs developed the same shedding after losing a similar share of their weight by other means.4
The third is the view reported by the dermatologists who reviewed the question. The hair loss "is likely secondary to metabolic stress or nutritional deficiency rather than a direct pharmacologic effect of the drug", and "no conclusive evidence directly implicates GLP-1RAs as toxic to hair follicles".3
The question is not fully closed. The same review notes that controlled trials have shown hair loss more often on the drugs than on placebo, which is what the label tables show, and calls for prospective studies. A placebo group loses little weight, so a trial cannot easily separate "the drug" from "the weight the drug took off".
Which types of hair loss have been linked to these drugs?
Mainly two. A meta-analysis published in 2026 pooled 17 studies of GLP-1 drugs and hair loss and worked out the odds for each type.5
Each bar starts at 1.00, which means no difference. Odds at 12 months compared with people not on these drugs, pooled from observational studies. Reports by drug come from side effect reports to regulators.
| Type of hair loss | What it is | Pooled odds on GLP-1 drugs |
|---|---|---|
| Telogen effluvium | diffuse shedding after a trigger | 1.76 times |
| Androgenetic alopecia | gradual pattern thinning | 1.64 times |
| Any non-scarring hair loss | the two above and others together | 1.40 times |
| Alopecia areata | patchy autoimmune loss | 1.08 times, not a clear difference |
Viquez Burboa and colleagues, Skin Appendage Disorders 2026.
The largest figure is for the trigger-related shedding described above. The second, pattern hair loss, is a different condition: a slow thinning at the crown and hairline. The meta-analysis cannot say why its odds were raised. The dermatology review notes in its own table that pattern hair loss is commonly found alongside shedding.
These are odds from observational studies, which compare people who chose to take a drug with people who did not, and from reports sent in by patients and doctors. They show that the signal is real across many sources. They are weaker evidence than the trial tables for how often it happens.
Why is it reported mostly by women?
The data show the difference and do not explain it. On Zepbound the figures were 7.1% for women and 0.5% for men, and on Wegovy 7.2 mg they were 8.4% and 0.2%. In the clinic study of weight-loss shedding, 110 of the 140 patients were women, and the authors conclude that "women and older adults are especially vulnerable", even though the women had been losing weight more slowly than the men, at 3.1 kg a month against 5.0.4
Part of the gap may be in who notices and who reports. Diffuse shedding is easier to see in longer hair, in the brush and in the shower drain. The trial figures are reports, so they reflect noticing as well as losing. None of the sources here measured that.
Does the hair grow back?
For the trigger-related kind, the reviews say yes. The 2026 review calls it "usually self-limited, with hair regrowth expected within 3–6 months once the weight is stabilized".3 In the clinic study the recovery period averaged 4.8 months, with a range from two weeks to 16 months.4
The follicles are not destroyed in this kind of shedding. They rest and start again, which is why the review's table of signs lists "upright regrowing hairs" among the things a dermatologist sees on the scalp. New hair grows slowly, so the gap between shedding stopping and hair looking full again is longer than the shedding itself.
The condition that matters here is "once the weight is stabilized". While the weight is still dropping quickly, the trigger is still present. This is why the calendar counts recovery from the week the weight levels off and not from the first dose. For most people on Zepbound that is somewhere between week 24 and week 60.7
Pattern hair loss is different. It does not reverse without treatment, and telling the two apart is the main reason to see a dermatologist if the shedding does not settle.
What do the reviews recommend?
The 2026 review lists its management steps for hair loss in people on these drugs.3
- Reassurance. The shedding is usually self-limited.
- Nutrition. "Ensure adequate protein intake and correct any micronutrient deficiencies." The lab findings it associates with this kind of shedding are low ferritin, low vitamin D and an abnormal thyroid test.
- The pace of weight loss. "Consider slowing dose escalation or stabilizing rapid weight loss."
- Staying on the drug. Stopping is "not required unless hair loss is severe, persistent, or significantly distressing".
- Treatment. The review names topical minoxidil among the options for shedding, and standard treatment for pattern hair loss.
- Referral. To a dermatologist "if the diagnosis is unclear, scarring alopecia is suspected, or no improvement occurs after 3–6 months".
The nutrition point connects to a separate document. A 2025 advisory from four medical societies on eating during GLP-1 treatment lists "excessive hair loss" among the signs of a real nutrient deficiency, next to unusual fatigue, muscle weakness and poor wound healing. It notes that food intake falls by 16% to 39% on these drugs, and gives 80 to 120 grams of protein a day as a practical target.6 The article on protein on GLP-1 drugs works that target out for your weight.
The pace point connects to the label. Zepbound's dose may be raised after "at least" 4 weeks on each step, so a slower climb is within the label, and a slower climb means slower weight loss.1 No trial has tested whether slowing the dose prevents shedding. It is the reviewers' suggestion, to be weighed with the prescriber.
How can I tell shedding from pattern hair loss?
The review sets the two side by side.3
| Shedding after a trigger | Pattern hair loss | |
|---|---|---|
| How it starts | diffuse shedding 2 to 3 months after a trigger | progressive thinning over years |
| Where | all over, often most at the sides | crown, top of the scalp and hairline |
| Hairs lost a day | more than 100 to 300 | 10 to 100 |
| Blood tests | often a deficiency, such as low ferritin or vitamin D | usually normal |
After Table 3 of Seyed Jafari and colleagues, 2026.
The two can occur together, and the review notes that pattern hair loss is common alongside shedding. A sudden increase in hairs on the pillow a few months into treatment points to shedding. A slow widening of the parting that began before treatment points to pattern loss, which the weight loss did not cause.
What can this page not tell you?
The window is a usual pattern, not a schedule. In the clinic study, shedding began anywhere from immediately to 6 months after the weight loss, and recovery took from two weeks to 16 months.
The trial figures are reports. Hair loss was recorded when a participant mentioned it. Nobody examined scalps.
The timing studies are not of Zepbound. They describe shedding after weight loss in general. No study here followed people on Zepbound from first shed hair to regrowth.
The odds come from observational data. The meta-analysis pooled cohort studies and side effect reports, which cannot separate the drug from the weight loss.
Short answers to common questions
Does Zepbound cause hair loss?
Hair loss is listed among its side effects: 7.1% of women and 0.5% of men reported it in the trials, against 1.3% and 0% on placebo. The label says it was associated with weight reduction.
When does it start?
Shedding of this kind usually appears 2 to 3 months after the weight loss that sets it off, so typically from the third month of treatment.
How long does it last?
Regrowth is expected within 3 to 6 months once the weight is stable. In a study of 140 people with weight-loss shedding, recovery took 4.8 months on average.
Will it grow back?
The dermatology review describes this shedding as usually self-limited. Pattern hair loss, a different condition, does not reverse by itself.
Do I have to stop Zepbound?
The review says stopping is not required unless the hair loss is severe, persistent or very distressing. Nobody on Zepbound left the trials because of hair loss.
Is it worse on a higher dose?
Not in the Zepbound table: 5, 4 and 5 in 100 on 5, 10 and 15 mg. On Wegovy the 7.2 mg dose, which took off more weight, came with more hair loss than 2.4 mg.
Is it worse on Zepbound than on Wegovy?
The label figures for women are 7.1% on Zepbound and 4% to 5.4% on Wegovy 2.4 mg, from separate trials with different weight losses. They were not compared directly.
Does protein or a supplement prevent it?
The review recommends adequate protein and correcting any deficiency found on blood tests. No trial here tested a supplement for preventing shedding on these drugs.
How the calendar works
The calendar treats the weeks in which weight is falling as the trigger. It opens the shedding window 9 weeks after the first dose, which is about two months, and keeps it open until 13 weeks after the fast phase of weight loss, taken as the first 24 weeks, or after the week you set if that is earlier. It places regrowth 13 to 26 weeks, three to six months, after the week your weight levels off. The timings are those given in the 2026 dermatology review for shedding after a trigger.
The dots chart shows the label figures for hair loss by sex, with the placebo figure in grey and the difference in coral, rounded to whole people. The odds chart shows the pooled results of the 2026 meta-analysis, drawn as the part of each figure above 1.00.
Sources
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2.1 and 6.1. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 6.1. accessdata.fda.gov
- Seyed Jafari SM, Caro G, Lipner SR, Iorizzo M. The impact of GLP-1 receptor agonists on hair: beneficial effects or adverse outcomes? Am J Clin Dermatol 2026;27:579-586. doi:10.1007/s40257-026-01021-6
- Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Ann Dermatol 2024;36:384-388. doi:10.5021/ad.24.043
- Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disord 2026. doi:10.1159/000553070
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
Related analyses
Your first week and first month on Zepbound: what to expect, by date
Zepbound plateau: when weight loss slows, why, and what the trials show
Mounjaro side effects: how common each one is by dose, and when they ease
Ozempic side effects: how common each one is by dose, and when they ease
Log your weight each week and the app shows when the fast phase ends.
Open Dose Insider